Humanin is an amino acid known to play many roles in the human body. Alzheimer’s disease defense may be one of those roles. Humanin is a potential therapeutic agent for Alzheimer’s disease, and its derivative, S14 G-humanin, is much stronger in its neuroprotective effect against Alzheimer’s disease-relevant insults. Although effective, the detailed molecular mechanism through which S14 G-humanin exerts its effects remains unclear.
A recent study by Xue Li and colleagues from Henan Provincial People’s Hospital, China investigated the inhibitory effects of S14G-humanin on amyloid-beta protein-induced hippocampal neuronal injury, and data from this study showed that fibrillar amyloid-beta 40 disturbed cellular homeostasis through the cell membrane, increasing intracellular calcium, generating reactive oxygen species, and decreasing the mitochondrial membrane potential. S14G-humanin blocked the effects of amyloid-beta 40 on the neuronal cell membrane, and restored the disturbed cellular homeostasis, thereby exhibiting a potential and effective treatment for Alzheimer’s disease.
These findings were published in the Neural Regeneration Research (Vol. 8, No. 27, 2013).
Gary Chandler is a prion expert. He is the CEO of Crossbow Communications, author of several books and producer of documentaries about health and environmental issues around the world. Chandler is connecting the dots to the global surge in neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, Creutzfeldt-Jakob disease, chronic wasting disease and other forms of prion disease. The scientific name for prion disease is transmissible spongiform encephalopathy. The operative word is “transmissible.” Even the global surge in autism appears to be related.